WIBR1
WIBRe003-A
General
Cell Line |
|
| hPSCreg name | WIBRe003-A |
| Cite as: | WIBRe003-A (RRID:CVCL_9765) |
| Alternative name(s) |
WIBR1
|
| Cell line type | Human embryonic stem cell (hESC) |
| Similar lines | No similar lines found. |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | Whitehead Institute for Biomedical Research (WIBR) |
| Owner | Whitehead Institute for Biomedical Research (WIBR) |
| Distributors | |
| Derivation country | United States |
External Databases |
|
| BioSamples | SAMEA185109 |
| Cellosaurus | CVCL_9765 |
| NIHhESC | NIHhESC-10-0074 |
| Wikidata | Q54994039 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | unknown |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | unknown |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46XY
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA104129951 |
Ethics
| Was the embryo established purely for research purposes? | No |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | NIHhESC-10-0074 |
| Alternative consent approval number | NIHhESC-10-0074 |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Whitehead Institute and NIH |
| Approval number | NIHhESC-10-0074 |
hESC Derivation
| Date of derivation | 2010-06-21 |
| Supernumerary embryos from IVF treatment? |
Yes
Separation of research and IVF treatment?
Yes |
| PGD Embryo? |
No |
| Derived under xeno-free conditions? |
No |
| Derivation under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
TrypLE
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|
|
|
| POU5F1 (OCT-4) |
Yes |
|
|
|
|
|
| SSEA-3 |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| TRA 1-81 |
Yes |
|
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
Passage number: 38
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.